First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects

Aims Human genetic, tissue expression, proteomics, transcriptomics and nonclinical studies implicate tumour necrosis factor α‐like ligand 1A (TL1A) as a novel target in inflammatory bowel disease (IBD). PF‐06480605, a fully human immunoglobulin G1 monoclonal antibody, targets TL1A. This first‐in‐hum...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of clinical pharmacology 2020-04, Vol.86 (4), p.812-824
Hauptverfasser:	Banfield, Christopher, Rudin, Dan, Bhattacharya, Indranil, Goteti, Kosalaram, Li, Gang, Hassan‐Zahraee, Mina, Brown, Lisa S., Hung, Kenneth E., Pawlak, Sylvester, Lepsy, Christopher
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Antibodies, Monoclonal Antibodies, Neutralizing Antineoplastic Agents, Immunological clinical trials Dose-Response Relationship, Drug Double-Blind Method Healthy Volunteers Humans inflammation monoclonal antibodies Original pharmacodynamic pharmacokinetic Phase 1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!